Full-Time

Lead Director

Healthcare Medicaid Risk Adjustment Analytics

Deadline 9/18/26
CVS Health

CVS Health

10,001+ employees

Healthcare, insurance, PBM, and retail pharmacy

Compensation Overview

$100k - $231.5k/yr

+ Bonus + Commission + Short-term incentive + Equity award

Company Historically Provides H1B Sponsorship

New Mexico, USA + 49 more

More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | California, USA | Washington, DC, USA | Vermont, USA | Wyoming, USA | Connecticut, USA | Texas, USA | Montana, USA | Florida, USA | New Hampshire, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Colorado, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Hartford, CT, USA | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Wisconsin, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | New Jersey, USA | Indiana, USA | Louisiana, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA

Remote

Bachelor's, Master's, MBA

Category
Data & Analytics (2)
,
Required Skills
Power BI
Python
SAS
Data Visualization
Data Science
Forecasting
BigQuery
SQL
Machine Learning
Data Engineering
Tableau
Databricks
Looker
Data Analysis
Snowflake

Get referred to CVS Health

See people who can refer or advise you

Requirements
  • At least 10 years of experience in healthcare analytics and reporting, including risk adjustment and relevant working knowledge of claims.
  • At least 3 years of leadership experience, including people management, coaching, or mentoring team members.
  • Advanced technical skills in SAS, SQL, Python, or cloud-based analytics platforms such as BigQuery, Snowflake, or Databricks.
  • Expertise in state and regulatory requirements, risk adjustment methodologies, and encounter data processes.
  • Strong knowledge of risk models such as CDPS, CRG, and HCC, and state reconciliation processes.
  • Proven ability to develop and execute strategic initiatives that deliver measurable business outcomes.
  • Demonstrated leadership experience managing cross-functional teams and large-scale programs.
  • Experience with data visualization tools such as Tableau, Power BI, QuickSight, or Looker.
Responsibilities
  • Define and execute Medicaid risk adjustment strategy across markets and plans.
  • Lead and deliver strategic initiatives that improve revenue accuracy, compliance, and overall performance.
  • Align risk adjustment programs with state Medicaid models, including CDPS, CRG, and state-specific methodologies.
  • Represent Medicaid risk adjustment informatics in executive forums to drive alignment on strategic goals and translate analytics into actionable financial and operational strategies.
  • Oversee health plan performance using advanced analytics and proactive data insights to drive strategies and evidence-based decision-making.
  • Lead development of scalable data pipelines and reporting frameworks using claims, encounter, pharmacy, and clinical data.
  • Lead advanced analytics for risk score development, predictive modeling, forecasting, trend analysis, and opportunity identification.
  • Ensure accuracy, integrity, and completeness of Medicaid encounter submissions and data.
  • Define data analysis methodologies and drive predictive and prescriptive analytics projects while communicating insights to key stakeholders.
  • Establish and oversee processes that ensure accuracy, completeness, and integrity of risk capture.
  • Lead reconciliation of plan-calculated risk scores to state-reported scores, including variance analysis and root-cause identification.
  • Monitor and validate encounter data submissions and their downstream impact on state risk scoring and payments.
  • Partner with actuarial and finance teams to align risk scores, revenue projections, and state payments.
  • Ensure readiness for state audits and external reviews through robust data validation and documentation practices.
  • Stay current on evolving Medicaid policies, state methodologies, and reporting requirements.
  • Direct suspecting logic development, gap identification, and prioritization strategies for operational programs and interventions.
  • Measure and evaluate program performance and identify opportunities for expansion, improvement, or savings.
  • Establish program key performance indicators to monitor intervention effectiveness.
  • Partner with clinical operations and vendor teams to ensure alignment with state requirements.
  • Align data strategies with value-based initiatives and provider-level drilldowns for consistent performance management across markets.
  • Lead and develop a multidisciplinary team spanning informatics, risk analytics, reporting, and operational program support.
  • Define organizational structure and align roles across strategy, analytics, and process execution to ensure end-to-end accountability.
  • Establish governance frameworks for prioritization and execution of risk adjustment initiatives.
  • Drive integration across analytics and operations so insights are translated into actionable intervention programs and measurable outcomes.
  • Develop talent strategy, including coaching and mentorship in advanced analytics, Medicaid risk models, and leadership capabilities.
  • Foster data integrity, accountability, and continuous improvement of workflows and analytic methodologies.
  • Ensure scalability and sustainability of operations by standardizing tools, reporting, and processes across markets.
  • Leverage automation and data infrastructure improvements to reduce manual effort and increase speed to insight.
Desired Qualifications
  • Knowledge of Medicaid risk adjustment.
  • Experience working with Medicaid risk models.
  • Master's degree in Health Informatics, Data Science, Actuarial, Statistics, or an MBA.
  • Experience working within a large national health plan or payer organization.
  • Bachelor's degree, specialized training, or a relevant professional qualification.

CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Woonsocket, Rhode Island

Founded

1963

Get referred to CVS Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 CVS raised adjusted EPS guidance to $7.90-$8.10 and revenue to $414 billion.
  • Walgreens plans roughly 1,200 U.S. store closures through 2027, sending prescription volume to CVS.
  • Teresa Heitsenrether joined the board September 2026, strengthening CVS’s data and digital execution focus.

What critics are saying

  • May 2026 340B lawsuits from Mount Sinai, Michigan, and Kansas attack Caremark’s remittance model.
  • CVS disclosed 2027 Caremark membership declines and continued 340B pressure on August 5, 2026.
  • If courts restrict 340B spreads or rebate flows, CVS loses a core profit engine.

What makes CVS Health unique

  • CVS Health combines Aetna, Caremark, and 9,000 pharmacies across one U.S. customer funnel.
  • August 5, 2026 results showed integrated pricing, insurance, and pharmacy scale outperformed standalone peers.
  • The August 2026 Eli Lilly collaboration embeds Zepbound and Foundayo access inside CVS channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Company Equity

Wellness Program

Professional Development Budget

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Sep 14th, 2026
CVS Health up 32% in a year: is it time to buy the stock?

CVS Health shares have declined 2.1% over the past three months, prompting investors to consider whether now is an opportune time to buy. The healthcare giant, which operates approximately 9,000 retail pharmacy locations and serves more than 35 million people through its health insurance business, reported second-quarter revenue of $106 billion, up 7.3% year-over-year. Adjusted earnings per share rose 43% in the same period. The company offers a dividend yield of 2.8%, with its annual payout increasing from $2 in 2021 to $2.66 per share recently. Shares currently trade at $95, with one analyst setting a price target of $120. The stock's forward price-to-earnings ratio of 11 sits slightly above its five-year average of 10.

Yahoo Finance
Sep 13th, 2026
US health insurers rebound as medical costs stabilise, analysts predict 16% earnings growth through 2030

The health insurance industry may have recovered from high medical costs, with analysts predicting strong growth through 2030. Morningstar forecasts 16% annual earnings per share growth for major insurers, above the industry's typical low-double-digit target. Health insurers are improving profitability by raising rates to cover increased medical utilisation. UnitedHealth Group reported over $5 billion in second-quarter net income, with its medical care ratio falling to 86.7% from 89.4% year-over-year. The outlook also improved for pharmacy benefit management operations at companies like UnitedHealth, CVS Health, and Cigna. Despite increased regulatory scrutiny, the "big three" PBMs maintain strong competitive positions. Third-quarter earnings reports next month should provide further clarity on the industry's financial health.

Yahoo Finance
Sep 12th, 2026
CVS quietly gains market share as Walgreens closes 1,200 US stores following $10B private equity sale

Walgreens is closing roughly 1,200 of its approximately 8,500 US locations through 2027, with many customers being redirected to nearby CVS pharmacies. The pattern is reshaping suburban pharmacy markets without direct competition. In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the 124-year-old chain private for the first time. Mike Motz was named chief executive, replacing Tim Wentworth. CVS is gaining market share without active expansion efforts. Federal and state rules require orderly prescription transfers when pharmacies close, often directing patients to the nearest CVS location. CVS and Walgreens together now handle nearly 40% of all US retail prescription sales. CVS benefits from owning Caremark, a dominant pharmacy benefit manager, providing vertical integration advantages.

Yahoo Finance
Aug 28th, 2026
CVS stock down 12% in a month despite 34% annual gain, faces 2027 headwinds

CVS Health stock has declined 12.3% over the past month, sitting about 15% below its 52-week high, though it remains up 34% over the trailing twelve months. The company's revenue reached approximately $415 billion, up 7.4% year-over-year. Management raised its full-year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10. For 2027, the company anticipates membership declines at Caremark and continued 340B programme pressure, offset by Aetna's recovery, which added over $2 billion in adjusted operating income in the first half of 2026. Management considers a 2027 adjusted EPS outlook of at least $8.44 reasonable. Historically, CVS has experienced varied recovery periods following market downturns, with some rebounds taking years rather than months.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.